Eisai Aricept "not approvable" for VaD
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eisai/Pfizer's Alzheimer's therapy Aricept (donepezil) is "not approvable" for vascular dementia claim, FDA says July 3. FDA found that the application contained insufficient information to support an approval at this time, the firm said. Eisai plans to have discussions with FDA as to the next regulatory step. FDA's Peripheral & Central Nervous System Drugs Advisory Committee was scheduled to review the sNDA May 16, but the meeting was cancelled. At a March 2001 meeting, the committee had debated whether VaD was a distinct clinical entity. Aricept is the first agent to be filed for VaD, but Janssen's Reminyl (galantamine) and Novartis' Exelon (rivastigmine) are both in Phase III for the condition (1Pharmaceutical Approvals Monthly Oct. 1, 2002, p. 23
You may also be interested in...
Eisai Submits Aricept VaD sNDA; Study Criteria Endorsed By Committee
Eisai/Pfizer are looking to expand Aricept’s approved indications to include vascular dementia based on two studies that enrolled patients using NINDS-AIREN diagnosis criteria.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.